Work

Serious adverse drug reactions to zolpidem: does impaired metabolic clearance and concurrent SSRI / SNRI use increase risk?

Year: 2016

Type: article

Abstract: Zolpidem is one of the most commonly used drugs for insomnia but it has been associated with adverse neuropsychiatric effects and complex sleep‐related behaviours. In this report, the pharmacokinetics, pharmacodynamics and putative serious adverse drug reactions (ADRs) to zolpidem are briefly described. Nine ‘hypothesis generating’ cases from a psychiatry practice are presented to suggest that in cytochrome P450 poor metabolisers, inhibitory metabolic drug–drug interactions and pharmacodynamic synergies with selective serotonin reuptake inhibitor/serotonin‐noradrenaline reuptake inhibitor antidepressants may increase the risk of serious ADRs to zolpidem.

Source: Journal of Pharmacy Practice and Research

DOI: 10.1002/jppr.1176

Authors: Thomas M. Polasek, Vidya Perera, Yolande Lucire

Institutions: Flinders University, University at Buffalo, State University of New York

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2436645838

FWCI: 0.243

Cites: 15

Cited by: 4

Related to: 10